C12N 2799/027
Where the vector is derived from a retrovirus
Official title: where the vector is derived from a retrovirus
C12N2799/027 (Where the vector is derived from a retrovirus) appears on 480 US grants and 697 published applications in this corpus.
Search patents in C12N- Granted patents
- 480
- Published applications
- 697
- Assignees
- 372
- Inventors
- 1,267
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 11 | 0 |
| 1998 | 22 | 0 |
| 1999 | 22 | 0 |
| 2000 | 26 | 0 |
| 2001 | 15 | 3 |
| 2002 | 18 | 66 |
| 2003 | 23 | 91 |
| 2004 | 25 | 55 |
| 2005 | 28 | 49 |
| 2006 | 25 | 42 |
| 2007 | 17 | 33 |
| 2008 | 17 | 29 |
| 2009 | 20 | 57 |
| 2010 | 23 | 59 |
| 2011 | 23 | 43 |
| 2012 | 24 | 27 |
| 2013 | 32 | 31 |
| 2014 | 19 | 23 |
| 2015 | 15 | 15 |
| 2016 | 13 | 13 |
| 2017 | 13 | 12 |
| 2018 | 10 | 10 |
| 2019 | 9 | 9 |
| 2020 | 4 | 8 |
| 2021 | 4 | 5 |
| 2022 | 6 | 6 |
| 2023 | 3 | 1 |
| 2024 | 1 | 5 |
| 2025 | 4 | 3 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene vector17 Mar 2026US 12,577,560 B2Fondazione Telethon
- Methods of producing modified natural killer cells and methods of use21 Oct 2025US 12,448,604 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Liver-specific nucleic acid regulatory elements and methods and use thereof9 Sep 2025US 12,409,236 B2Life Sciences Research Partners VZW
- Inducible T cell receptors and uses thereof17 Jun 2025US 12,331,095 B2Medigene Immunotherapies GmbH
- Methods for manufacturing adoptive cell therapies6 May 2025US 12,291,722 B22seventy bio, Inc.
- Combination cancer therapy14 May 2026US 2026/0131028 A1Delta Next-Gene, LLC
- 3d cell culture methods5 Feb 2026US 2026/0035661 A1Fondazione Telethon Ets (50%)
- Rna engineered t cells for the treatment of cancer6 Nov 2025US 2025/0340869 A1The Trustees of the University of Pennsylvania
- Methods for manufacturing adoptive cell therapies18 Sep 2025US 2025/0290041 A12seventy bio, Inc.
- T cell receptors17 Apr 2025US 2025/0122263 A1Adaptimmune Limited
Most cited
By later US patents
- Humanized green fluorescent protein genes and methods264US 5,874,304 AUniversity of Florida Research Foundation, Inc. · 1999
- High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")235US 6,040,177 AFred Hutchinson Cancer Research Center · 2000
- Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects229US 5,716,616 AThomas Jefferson University · 1998
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Nuclear reprogramming factor151US 8,048,999 B2Kyoto University · 2011